Medtronic (MDT)

The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports—including PPE, consumables, and medical devices—to assess reliance on foreign suppliers for critical health products.

Surgical technology is advancing quickly, and robots are the future, which is why you'll want to look at this high-yield surgical robot maker.

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on the burgeoning market for weight-loss and diabetes drugs, driven by its groundbreaking GLP-1 agonists. In stark contrast, Johnson & Johnson (NYSE:

Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter for 2025. The company's performance was marked by significant growth across its Innovative Medicine and MedTech segments, showcasing the strategic success of its

Medtronic is one of the largest medical device makers in the world, and it is focused on getting more profitable.

Medtronic's Altaviva wins FDA approval as a minimally invasive implant for urge urinary incontinence, offering long-lasting and low-maintenance therapy.

In a financial landscape increasingly dominated by the exhilarating, often volatile, narrative of artificial intelligence, Intuitive Surgical (NASDAQ: ISRG) stands as a testament to steady, fundamental innovation. As the market's gaze fixates on every whisper of AI advancement, the pioneer of robotic-assisted surgery continues its work, quietly refining its formidable

Sunnyvale, CA – September 17, 2025 – Intuitive Surgical (NASDAQ: ISRG), the pioneer and global leader in robotic-assisted surgery, has once again demonstrated its formidable market position with a robust second-quarter 2025 earnings report. The company announced an impressive adjusted Earnings Per Share (EPS) of $2.19, significantly surpassing analyst expectations, coupled

The storied medical device specialist always seems to post encouraging growth.

Find out how the company's da Vinci surgical robots could remain the preferred option for decades.

Medtronic (MDT) offers a strong 3.01% dividend yield, a history of reliable payouts, and solid profitability, making it a top candidate for sustainable income investors.

An unbeatable advantage makes this stock a popular one among billionaire investors.

They have increased their payouts for a combined 111 straight years.

The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is fundamentally altering the landscape of medical treatment and diagnostics, promising a future of more personalized, precise, and preventive medicine. At the forefront of this

Medtronic plc is a global medical device manufacturer with leadership positions in the pacemaker, defibrillator, orthopedic, diabetes management, and other medical markets.

These robotics leaders are positioned to capitalize as AI transforms machines from tools into intelligent partners.

The market may be overlooking these companies' long-term potential.

MDT stock shows strong technical momentum and a high-quality consolidation pattern, suggesting a potential breakout setup with a clear risk-reward entry point.

These income stocks offer above-average yields, have strong fundamentals, and should offer investors a lot of stability over the long run.

Medtronic's Hugo robotic-assisted surgery system showed strong safety and effectiveness in a U.S. hernia repair study, meeting all key clinical goals.

The U.S. stock market is navigating a turbulent start to September 2025, with major indexes experiencing notable declines after a strong August rally. This early-month pullback is being attributed to a confluence of factors, including rising bond yields, persistent inflation concerns, escalating geopolitical tensions, and the historically recognized "September

Companies that have increased their dividends annually for 25 consecutive years are a rare breed. These three also stand out for their attractive yields.